William H Rastetter
CIK 1205903 · last filed 2026-10-19
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RCPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IAM | Director | 192,579 | — | — | $0 | 2 | 2026-10-19 |
| DARE | Director | 39,721 | $0.65 | $26.0K | $0 | 12 | 2026-07-02 |
| FATE | Director | 495,603 | $2.08 | $1.03M | $1.50M | 17 | 2026-06-15 |
| NBIX | Director | 43,678 | $146.10 | $6.38M | -$13.07M | 27 | 2026-05-29 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 57,292 | $8.16 | $467.5K | $1.65M | 26 | 2025-06-27 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 10,304 | — | — | $0 | 4 | 2017-01-05 |
| ILMN | Director | 95,174 | $277.63 | $26.42M | -$9.29M | 31 | 2016-01-04 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | -$16.60M | 8 | 2015-08-27 |
Recent Filings · Page 4 of 14
132 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-03 | NBIX | Mixed | +3,325 | -$339.2K | EDGAR |
| 2023-05-01 | NBIX | Notice (144) | −4,300 | -$434.5K | EDGAR |
| 2023-04-21 | NBIX | Mixed | +5,438 | -$571.3K | EDGAR |
| 2023-04-19 | NBIX | Notice (144) | −11,216 | -$1.16M | EDGAR |
| 2022-06-24 | DARE | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | FATE | Grant (A) | +8,650 | $0 | EDGAR |
| 2022-06-10 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | NBIX | Grant (A) | — | $0 | EDGAR |
| 2022-04-05 | NBIX | Mixed | +9,272 | -$885.2K | EDGAR |
| 2021-06-24 | DARE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.